OX40 receptor

OX40 is a protein found on the surface of activated immune cells called T cells. When OX40 is engaged by its partner molecule (OX40L), it acts like a gas pedal that helps T cells multiply, survive longer, and mount a stronger attack, including attacks against tumor cells. Because of this role, OX40 has become a target for experimental cancer immunotherapy drugs.

Origin

OX40 was first described in the late 1980s at the University of Oxford, where researchers used a series of monoclonal antibodies to identify activation markers on rat T cells. "OX" refers to Oxford and "40" was its position in that antibody panel. It is also known scientifically as CD134 or TNFRSF4 (tumor necrosis factor receptor superfamily member 4).

Significance in Asbestos Context

For mesothelioma and asbestos-related lung cancer patients, OX40 matters because it is one of several immune checkpoint and co-stimulatory pathways being studied to make immunotherapy work better. Mesothelioma is considered relatively "cold" to the immune system, and OX40 agonist drugs, sometimes combined with PD-1 or CTLA-4 inhibitors like nivolumab or ipilimumab, are being tested to wake up a stronger anti-tumor response. Patients considering clinical trials may see OX40-targeted agents listed as eligibility options, and tumor biopsies are sometimes tested for OX40 or OX40L expression to help match patients to trials.

Example Sentence

Her oncologist mentioned that an early-phase clinical trial combining an OX40 agonist with standard immunotherapy was open to mesothelioma patients at the academic cancer center.

Related Terms

Immunotherapy, Checkpoint inhibitor, T-cell, PD-L1, Tumor microenvironment, Clinical trial

Notes

• If you are exploring immunotherapy options, ask your oncologist whether any OX40-targeted clinical trials are open for mesothelioma or asbestos-related lung cancer, and search ClinicalTrials.gov using "OX40" and your diagnosis.
• Request that your diagnostic tumor block be preserved and ask whether immune profiling (PD-L1, tumor-infiltrating lymphocytes, and where available OX40/OX40L) has been performed. These results can determine trial eligibility.
• OX40-targeted drugs are not yet FDA-approved for asbestos-related cancers; if offered, it will almost always be through a clinical trial, and trial participation should be documented in your medical records for both treatment and legal claim purposes.
• Keep copies of all pathology and immunohistochemistry reports; they may support both future treatment decisions and damages calculations in a legal claim.